With 23 years of deep cultivation in the field of original new drugs,We have gained a high degree of recognition and encouragement from the industry.
In July, Dr. Lu Xianping, Chairperson of Chipscreen Biosciences, was recognized as one of the "20 Innovation Pioneers in China New Drug Innovation over 20 Years" by Tonacea; Chidamide was named one of the "20 Drugs in China New Drug Development over 20 Years".
In July, Chipscreen Biosciences received the "2024 Yinghua Award for Innovation in A-Share Investment" from the China Fund News; Ms. Hai Ou, Deputy General Manager and Secretary of the Board, was honored with the 2024 "Board Secretary of the Year" Gold Medal Award by Shanghai United Media Group and the Jiemian News.
In July, Chiglitazar Sodium received the "China First-in-Class New Drug of the Same Class and China First-in-Class Targeted Drug" award from the Chinese Biopharmaceutical Association-USA (CBA-China) and Pharmacodia.
In June, Chipscreen Biosciences was named one of the "2023 Top 30 Chinese Innovative Enterprises in Small Molecule Drugs" by Minet.
In June, Ms. Hai Ou, Deputy General Manager and Secretary of the Board at Chipscreen Biosciences, received the Tianma Award for "Best Board Secretary to Investor Relations of Chinese Listed Companies" from the Securities Times.
In January, Chipscreen Biosciences was awarded the "Head Strength — Pharmaceutical Company with High-Quality Development Achievements in China" by the Medicine Economic News, and our innovative drug Chiglitazar Sodium was named the "Head Strength — Pharmaceutical Brand with High-Quality Development Achievements in China (2023)".
In January, Chipscreen Biosciences was named among the "Top 100 Most Popular Listed Companies of 2023" by Tonghuashun (300033) and Ms. Hai Ou, Deputy General Manager and Secretary of the Board, was recognized as one of the "Top 100 Most Popular Board Secretaries of 2023."
In December, Chengdu Chipscreen Pharmaceutical was included in the 2023 Chengdu New Economy Demonstration Enterprise List issued by the Chengdu New Economy Development Leading Group Office
In November, Chipscreen Biosciences received the annual China Fortune "Golden Lion" pioneering enterprise award for high-quality and sustainable development from the China Fortune Network, a financial media platform under the Xinhua News Agency
In November, Chengdu Chipscreen Pharmaceutical was accredited as a "Gazelle Enterprise" by the Chengdu Hi-tech Zone Management Committee
In October, Chipscreen Biosciences was selected as one of the "2023 Forbes China ESG Innovation Enterprises" and awarded the "2023 ESG Model Enterprise Award for Listed Companies" by Time Media Group
In October, Chipscreen Biosciences was rated A in the SSE's first information disclosure rating of listed companies on the Sci-Tech Innovation Board
In September, Chengdu Chipscreen Pharmaceutical was included in the 2023 Sichuan New Economy Demonstration Enterprise List jointly released by the Sichuan Provincial Department of Economy and Information and the Sichuan Provincial Department of Finance
In August, Chengdu Chipscreen Pharmaceutical was certified as a "specialized, high-end and innovation-driven SME of Sichuan Province" by the Sichuan Provincial Department of Economy and Information
In June, the project "Development and Application of Chidamide, a Novel Epigenetic Modulator and Anti-Tumor Drug" was awarded first prize in the 2022 Shenzhen Technological Invention Award by the Shenzhen Municipal People's Government;
In June, Chipscreen Biosciences was named one of the "Top 30 Chinese Innovative Enterprises in Small Molecule Drugs" in the "2022 Top 100 Chinese Innovative Biopharmaceutical Enterprises" list issued by Menet
In February, our innovative drug chidamide was awarded the "Head Strength — Pharmaceutical Brand with High-Quality Development Achievements in China (2022)" by the Medicine Economic News
In February, Chipscreen Biosciences was awarded the "Head Strength — Pharmaceutical Company with High-Quality Development Achievements in China" by the Medicine Economic News
In November, Chengdu Chipscreen Pharmaceutical Ltd. was certified as a national high-tech enterprise for the first time.
In August, Chipscreen Biosciences' innovative new drug Chiglitazar was rewarded with the Annual New Drug Innovation Award (Domestic) of the "14th Healthy China Forum" issued by People's Daily Health Client and People's Daily Health Times.
In November, Dr. Lu Xianping, Chairman of Chipscreen Biosciences, was awarded the “2021 CABS K. Fong Award in Life Sciences” by the Chinese American Biopharmaceutical Society (CABS).
In October, Chidamide, as a significant technological achievement in the field of medicine, was invited to participate in the national "13th Five-Year Plan" scientific and technological innovation achievement exhibition co-sponsored by the Ministry of Science and Technology, the National Development and Reform Commission, the Ministry of Finance, the Equipment Development Department of the Central Military Commission of the P.R.C., the Science and Technology Commission under the Central Military Commission of the P.R.C., and the Beijing Municipal People's Government, and appeared on Network News Broadcast of CCTV.
In May, Chidamide, as a significant technological achievement in the field of medicine, was selected for the "Centennial Review: The Communist Party of China Leading the Development of Science and Technology" exhibition hosted by the Ministry of Science and Technology of the P.R.C. during the 2021 National Science and Technology Week.
In October, Chipscreen Biosciences was honored as an Outstanding Growth Enterprise of China’s Pharmaceutical Industry and an Outstanding Product Brand by the China Pharmaceutical Industry Association.
In December, Chidamide received a gold award in the 19th Chinese Patent Awards jointly issued by the China National Intellectual Property Administration and the World Intellectual Property Organization.
In March, Chidamide was recognized as the Chinese pharmaceutical brand with the most clinically valuable innovative drugs in 2016 by the Chinese Academy of Medical Sciences, People’s Daily Online and China Pharmaceutical Innovation and Research Deve
In September, Dr. Lu Xianping, Chairman of Chipscreen Biosciences, was awarded the first Pacific Life Science Achievement Award during the 11th Annual Meeting of the Sino-American Biotechnology and Pharmaceutical Association (SABPA).
In September, Dr. Lu Xianping, Chairman of Chipscreen Biosciences, was selected as one of Forbes magazine’s top 10 2015 Sino-American innovators.
In September, Chipscreen Biosciences won the BayHelix and BioCentury Award for R&D Achievement of the Year 2014.
In November, Chipscreen Biosciences was honored as Most Valuable Partner of Roche R&D Center (China).
In October, Chipscreen Biosciences was included in Deloitte’s 2008 China Fast 50 and China Tech Fast 50 lists.
In August, Chipscreen Biosciences was selected as one of the Top 10 Companies to Watch at the Asia-Pacific Life Sciences and Technology Summit.
